Sacituzumab Govitecan (Trodelvy)

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses sacituzumab govitecan (Trodelvy) 180 mg lyophilized powder for solution for injection, for IV use. Indication: For the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received 2 or more prior therapies, at least 1 of them for metastatic disease.